Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

Perianal Crohn Disease after Treatment with Rituximab for Active Granulomatosis with Polyangiitis

DAVID FRASER, STEPHEN BOYLE and NICOLE AMFT
The Journal of Rheumatology December 2016, 43 (12) 2199-2200; DOI: https://doi.org/10.3899/jrheum.160456
DAVID FRASER
Rheumatology Department, Western General Hospital;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEPHEN BOYLE
Rheumatology Department, Western General Hospital;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: boyledoc@yahoo.co.uk
NICOLE AMFT
Rheumatology Department, Western General Hospital, Edinburgh, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

Rituximab (RTX) in combination with glucocorticoids has been recommended for relapsing granulomatosis with polyangiitis (GPA) if the disease remains active after a course of cyclophosphamide (CYC) lasting 3–6 months1. We describe a case of perianal Crohn disease (CD) in a patient with GPA who had been treated with RTX.

A 24-year-old woman with GPA was diagnosed in 2006 with bilateral cavitating pulmonary lesions on computed tomography, pauciimmune glomerulonephritis with crescents and extraglomerular arteritis on renal biopsy, mononeuritis multiplex, and proteinase 3 (PR3)-antineutrophil cytoplasmic antibodies (ANCA) of > 100 U/ml. Six pulses of CYC with methylprednisolone were administered in 2006, but the patient experienced pulmonary and uveal recurrence of her GPA 5 weeks later. She had 1 course of 2 infusions of RTX (1 g per infusion) in combination with CYC in November 2006 (total cumulative CYC dose 7.5 g). In 2008 she developed headaches secondary to GPA recurrence affecting the pituitary gland confirmed by transsphenoidal biopsy and resulting in adrenocorticotropic hormone deficiency and cranial diabetes insipidus. She received 1 further course of RTX infusion in June 2008 with a further relapse (recurrence of headaches) in November 2009. Because azathioprine (AZA), methotrexate, and mycophenolate mofetil had been ineffective maintenance therapy, she began 6-monthly RTX infusions for 2 years. She received single RTX infusions (1 g each) in November 2009, August 2010, January 2011, and July 2011.

In April 2013 she developed perineal ulceration with granulation tissue on biopsy. The perineal disease progressed over the next year and developed into marked perianal ulceration by April 2014. Biopsy of the perineal skin showed mixed inflammatory cell infiltrate and colonoscopy was macroscopically normal. Microscopy revealed mild inflammatory changes with focal cryptitis, a preponderance of eosinophils not typical for inflammatory bowel disease (IBD), and crypt abscess formation. Magnetic resonance imaging (MRI) of the pelvis showed acute inflammation only. It was thought that the perianal ulceration was because of a recurrence of GPA and a further course of RTX was given in May 2014 (total cumulative RTX dose 10.8 g). The patient was readmitted in September 2014 with worsening perianal pain, ulceration, and discharge (Figure 1). The perianal skin showed evidence of fissures and progressive ulceration. Repeat MRI pelvis revealed extensive fistulating disease with a marked rectovaginal fistula, and perianal skin biopsies showed granulomata, consistent with CD. Repeat colonoscopy and colonic biopsies were normal. Swabs grew perineal skin commensals and tuberculosis and herpes simplex virus swabs were negative. The patient is currently receiving treatment with AZA and infliximab for her CD with good effect (complete resolution of the 3 fistula).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Perineal ulceration.

ANCA are common in both GPA and IBD, and cytoplasmic-staining ANCA reacting with PR3 is predominantly found in GPA, but may be found in CD2. GPA can present similarly to CD and CD can mimic GPA, but it is thought that the presence of both conditions is exceptionally rare, with 1 case report series identifying only 13 patients over 20 years2.

RTX is a chimeric anti-CD20 monoclonal antibody that targets B cell lymphocytes. Both B and T cells have been implicated in the pathogenesis of GPA3,4 and IBD. It has been suggested that B cells may not have a proinflammatory role in IBD and may have a protective effect, reducing inflammation by producing the antiinflammatory cytokine IL-105. There are only a few reports in the literature of induction or exacerbation of IBD by RTX.

A report of a 58-year-old man who underwent RTX salvage therapy for severe ulcerative colitis (UC) resulted in greatly depleted local and systemic CD20+ B cells, but the patient experienced a severe exacerbation of UC5. Two similar reports describe a 62-year-old woman with disseminated B cell lymphoma and a 67-year-old man with follicular lymphoma who both developed fulminant colitis after RTX therapy6,7. Both patients required surgery after not responding to medical therapy. Other reports describe UC in a 4-year-old boy after receiving RTX for nephrotic syndrome, which responded to corticosteroids8, and a 45-year-old woman with Grave disease with new-onset UC and arthritis following RTX9.

Conversely, RTX was not associated with worsening of UC in a double-blinded randomized controlled trial consisting of 24 patients with moderately active UC10.

Colitis may be associated with hypogammaglobulinemia. This has been reported with cytomegalovirus colitis in a patient with rheumatoid arthritis11, and in association with common variable immunodeficiency12. Our patient had normal immunoglobulin (Ig) levels prior to RTX therapy. However, thereafter the patient had low IgM (0.11–0.22 g/l) following the first RTX course until April 2012, when the level normalized. Low IgG (5.6 g/l) was noted after the last RTX course in May 2014.

RTX is effective in relapsing, refractory GPA. As shown in our case, RTX could induce or exacerbate IBD. Our patient had a normal colonoscopy with mild inflammatory changes on biopsy and perianal granulomata.

REFERENCES

  1. 1.↵
    1. National Institute for Health and Care Excellence
    . Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [Internet. Accessed September 27, 2016.] Available from: www.nice.org.uk/guidance/ta308?unlid=829516852016127114125
  2. 2.↵
    1. Vaszar LT,
    2. Orzechowski NM,
    3. Specks U,
    4. Ytterberg SR,
    5. Loftus EV Jr,
    6. Mark EJ,
    7. et al.
    Coexistent pulmonary granulomatosis with polyangiitis (Wegener granulomatosis) and Crohn disease. Am J Surg Pathol 2014;38:354–9.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Hinze CH,
    2. Colbert RA
    . B-cell depletion in Wegener’s granulomatosis. Clinic Rev Allerg Immunol 2008;34:372–9.
    OpenUrl
  4. 4.↵
    1. Savage CO,
    2. Harper L,
    3. Holland M
    . New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis. Curr Opin Rheumatol 2002;14:15–22.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Goetz M,
    2. Atreya R,
    3. Ghalibafian M,
    4. Galle PR,
    5. Neurath MF
    . Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis 2007;13:1365–8.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Lipka S,
    2. Katz S,
    3. Zia R,
    4. Crawford J,
    5. Ramek J
    . Fulminant colitis following rituximab therapy for disseminated B cell marginal lymphoma: P-16. Inflamm Bowel Dis 2012;18:S19–20.
    OpenUrl
  7. 7.↵
    1. Blombery P,
    2. Prince HM,
    3. Levinson M,
    4. Pianko S,
    5. Maxwell E,
    6. Bhathal P
    . Rituximab-induced immunodysregulatory ileocolitis in a patient with follicular lymphoma. J Clin Oncol 2011;29:e110–2.
    OpenUrlFREE Full Text
  8. 8.↵
    1. Ardelean DS,
    2. Gonska T,
    3. Wires S,
    4. Cutz E,
    5. Griffiths A,
    6. Harvey E,
    7. et al.
    Severe ulcerative colitis after rituximab therapy. Pediatrics 2010;126:e243–6.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. El Fassi D,
    2. Nielsen CH,
    3. Kjeldsen J,
    4. Clemmensen O,
    5. Hegedüs L
    . Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves’ disease. Gut 2008;57:714–5.
    OpenUrlFREE Full Text
  10. 10.↵
    1. Leiper K,
    2. Martin K,
    3. Ellis A,
    4. Subramanian S,
    5. Watson AJ,
    6. Christmas SE,
    7. et al.
    Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 2011;60:1520–6.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Vallet H,
    2. Houitte R,
    3. Azria A,
    4. Mariette X
    . Cytomegalovirus colitis and hypo-IgG after rituximab therapy for rheumatoid arthritis. J Rheumatol 2011;38:965–6.
    OpenUrlFREE Full Text
  12. 12.↵
    1. Borba de Arruda SM,
    2. do Rego Silva AM,
    3. Cezário de Barros KS,
    4. Cunha AM
    . Ulcerative colitis and common variable immunodeficiency: case report. Inflamm Bowel Dis 2009;15:478–81.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 43, Issue 12
1 Dec 2016
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Perianal Crohn Disease after Treatment with Rituximab for Active Granulomatosis with Polyangiitis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Perianal Crohn Disease after Treatment with Rituximab for Active Granulomatosis with Polyangiitis
DAVID FRASER, STEPHEN BOYLE, NICOLE AMFT
The Journal of Rheumatology Dec 2016, 43 (12) 2199-2200; DOI: 10.3899/jrheum.160456

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Perianal Crohn Disease after Treatment with Rituximab for Active Granulomatosis with Polyangiitis
DAVID FRASER, STEPHEN BOYLE, NICOLE AMFT
The Journal of Rheumatology Dec 2016, 43 (12) 2199-2200; DOI: 10.3899/jrheum.160456
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Duration of Steroid Therapy and Temporal Artery Biopsy Positivity in Giant Cell Arteritis: A Retrospective Cohort Study
  • Desk Rejections: Not Without Due Deliberation
  • COVID-19 and IgA Vasculitis
Show more Letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire